On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.<\/p>\n
Capivasertib, used in combination with fulvestrant (Faslodex), is indicated for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within twelve months of completing adjuvant therapy.<\/p>\n
TRUQAP (capivasertib) tablets is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.<\/p>\n
If TRUQAP (capivasertib) tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN.<\/strong>\u00a0For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query.\u00a0Like 1. How to get access in in India. 2. Medicine Price. 3. Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia. 4. Ensuring 100% transparency.\u00a0<\/strong><\/p>\n TRUQAP (capivasertib) tablets can be made available to patients, doctors, and hospitals in Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.<\/p>\n To receive comprehensive support, please call us at\u00a09811747774<\/a>,\u00a09891296838<\/a>\u00a0or WhatsApp at\u00a09811747774<\/a>,\u00a09891296838\u00a0<\/a>or email us at\u00a0info@indianpharmanetwork.co.in\u00a0<\/a> for TRUQAP (capivasertib) tablets in India.<\/strong><\/p>\n NEWS \/ UPDATES<\/strong><\/p>\n Note:<\/strong><\/em> Truqap works\u00a0to treat breast cancer<\/b>\u00a0by blocking the AKT enzyme. This enzyme becomes active in tumors due to unusual genes such as PIK3CA, AKT1, or PTEN. Blocking this enzyme stops the cancer from growing and spreading. * In this article, we use the terms \u201cmale\u201d and \u201cfemale\u201d to refer to someone’s sex assigned at birth.<\/p>\n\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Brand Name: TRUQAP Generic Name: capivasertibb. It is used to treat breast cancer.<\/h2>\n